Abattis Names William Fleming as CEO, Mike Withrow to Become International Business Lead

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 27, 2015) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK:ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that William (Bill) Fleming, as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp. effective February 1, 2015. He will succeed Mike Withrow, who is resigning his role as CEO and President to become International Business Advisor for Abattis and promote, develops, and manage opportunities for Abattis Bioceuticals Corp.

Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. Mr. Fleming has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies. Mr. Fleming is a member of the Qalipu Mi'kmaq First Nation and has provided Advisory Consulting services to Health Canada under the Public Health Information Surveillance program. Mr. Fleming is the Founder of Mernova Medicinal Inc., an Aboriginal owned company focused on becoming a Canadian producer of legal marijuana. Mr. Fleming is a graduate of St. Francis Xavier University and a recipient of the Canadian Armed Forces ROTP Scholarship.

Mike Withrow will continue to serve as International Business Advisor for strategic development.

The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor and strategic development, continue to seek out global opportunities for the expansion of the corporation's activities.

Jaouad Fichtali was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, has resigning the position of CTO and will be assuming the role of Extraction Advisor effective immediately. This will allow the Company to conserve resources until the time when a CTO becomes vital.

Incentive Stock Options

The Company also announces that its Board of Directors has granted incentive stock options to purchase up to 175,000 common shares of the Company at a price of $0.16 per share for a period of five years to its directors, officers and consultants. The grant of stock options is subject to regulatory approval.